Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
复制标题
DOI：
10.1016/j.bbmt.2019.08.003
复制
发表时间：
2020-01-01
影响因子：
4.3
通讯作者：
Bar, Merav
中科院分区：
文献类型：
--
作者：
Cordeiro, Ana;Bezerra, Evandro D.;Bar, Merav
靶向CD 19的嵌合抗原受体修饰的T细胞（CAR-T细胞）疗法在复发性难治性B细胞恶性肿瘤患者中显示出优异的抗肿瘤活性，具有非常令人鼓舞的缓解率和结局。然而，这种疗法的晚期效应仍然未知。在这里，我们报告了晚期不良事件-定义为在CAR-T细胞输注后开始或持续超过90天-在治疗后存活至少1年的患者中。中位随访时间为28.1个月（范围：12.5 - 62.6个月）。在末次随访时，73%的患者仍然存活，24%的患者处于持续完全缓解（CR）状态。最常见的晚期不良事件是低丙种球蛋白血症（IgG
CD19-targeted chimeric antigen receptor-modified T cell (CAR-T cell) therapy has shown excellent antitumor activity in patients with relapsed refractory B cell malignancies, with very encouraging response rates and outcomes. However, the late effects following this therapy remain unknown. Here we report late adverse events-defined as starting or persisting beyond 90 days after CAR-T cell infusion-in patients who survived at least 1 year after therapy. The median duration of follow-up was 28.1 months (range, 12.5 to 62.6 months). At last follow-up, 73% of patients were still alive and 24% were in ongoing complete remission (CR). The most common late adverse event was hypogammaglobulinemia (IgG